Corcept stock plunges 25% after Federal Circuit rules Teva's generic Korlym doesn't infringe patents. What it means for the $800M Cushing's drug franchise.

Corcept Therapeutics Crashes 25% After Federal Appeals Court Clears Teva Generic

Corcept's relacorilant extends ovarian cancer survival by 4.1 months in Phase 3 trial, cutting death risk 35%. FDA decision July 2026.

Leadership at CORCEPT THERAPEUTICS

Executives at CORCEPT THERAPEUTICS

Joseph K. Belanoff, M.D.

Atabak Mokari

Charles Robb

Hazel Hunt, Ph.D.

Joseph D. Lyon

Sean Maduck

William Guyer, Pharm.D.

Board Members at CORCEPT THERAPEUTICS

Daniel N. Swisher, Jr.

David L. Mahoney

G. Leonard Baker, Jr.

Gregg Alton

James N. Wilson

Joshua M. Murray

Kimberly Park

Recent News about CORCEPT THERAPEUTICS

Corcept Therapeutics Crashes 25% After Federal Appeals Court Clears Teva Generic

Corcept's Ovarian Cancer Drug Extends Lives by 4 Months in Pivotal Trial, Stock Whipsaws

Corcept Crashes 50% After FDA Rejects Relacorilant for Cushing's Syndrome